- Patients receiving clozapine (Clozaril, FazaClo, Versacloz) or a long-acting injectable antipsychotic experienced no worsening of symptoms or side effects when switched to monotherapy.
- Patients who switched to oral, nonclozapine antipsychotic (NCAP) experienced reduced side effects but also increased symptoms.
Why this matters
- Chronically ill patients may face some symptom risks when switching from polypharmacy to monotherapy, but benefits are also possible.
- In chronically ill patients switching to monotherapy, clozapine or an injectable antipsychotic may be the best choice.
- Patients with schizophrenia or schizoaffective disorder earlier treated with oral NCAP (n=45) or clozapine/injectable antipsychotics (C/IAP; n=45) were switched to monotherapy (n=43) or continued with polypharmacy (n=47).
- Funding: Florida Agency for Health Care Administration.
- Overall trajectory of change (using The Positive and Negative Syndrome score [PANSS]) with C/IAP showed significant increase on PANSS Negative Syndrome Scale scores (18.53; P<.001>
- Switch patients showed no significant time-by-condition interactions for any symptom or side effects (except Simpson Angus scale, P=.037) in C/IAP.
- Overall trajectory was positive with oral NCAP, indicating increased symptoms over time.
- Oral NCAP had significant interactions for BMI (P=.034), HbA1c (P=.035), and Abnormal Involuntary Movement Scale total score (P=.043).
- Requires cautious interpretation.
Coauthored with Chitra Ravi, M.Pharm